Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer

NCT02567422 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

43

Enrollment

NIH

Sponsor class

Conditions

Head and Neck Carcinoma of Unknown Primary
Head and Neck Squamous Cell Carcinoma
Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7
Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7
Stage III Sinonasal Squamous Cell Carcinoma AJCC v6 and v7
Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7
Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7
Stage IV Sinonasal Squamous Cell Carcinoma AJCC v7

Interventions

DRUG: Berzosertib
DRUG: Cisplatin
PROCEDURE: Computed Tomography
OTHER: Laboratory Biomarker Analysis
PROCEDURE: Magnetic Resonance Imaging
PROCEDURE: Positron Emission Tomography
RADIATION: Radiation Therapy

Sponsor

National Cancer Institute (NCI)